The integration of BNP and NT-proBNP into clinical medicine

Swiss Medical Weekly

Volumn 137, Issue 1-2, 2007, Pages 4-12

  Mueller, Christian ^a   Breidthardt, Tobias ^b   Laule Kilian, Kirsten ^b   Christ, Michael ^b   Perruchoud, André P ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

B type natriuretic peptide; Diagnosis; Dyspnoea; Heart failure

Indexed keywords

AMINOTERMINAL PROBRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; NEUROHORMONE; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DYSPNEA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE; HUMAN; INTENSIVE CARE UNIT; LONG TERM CARE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIVATE PRACTICE; REVIEW; RISK ASSESSMENT;

EID: 33846656236     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Mueller C, Buser P. B-type natriuretic peptide (BNP): Can it improve our management of patients with congestive heart failure? Swiss Med Wkly. 2002;132:618-22.
2. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2001;104:2996-3007.
3. Task Force for the Diagnosis and Treatment of Chronic heart Failure, European Society of Cardiology: W.J. Remme and K. Swedberg. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-60.
4. The Task Force on Acute Heart Failure of the European Society of Cardiology. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J. 2005;26:384-416.
5. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-53.
6. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure. Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-22.
7. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-12.
8. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
9. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet. 1994;343:440-4.
10. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
11. Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure. Comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47:742-8.
12. Watanabe S, Shite J, Takaoka H, et al. myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure. Eur Heart J. 2006;27:832-8.
13. Troughton RW, Prior DL, Pereira JJ, et al. Plasma B-type natriuretic peptide levels in systolic heart failure. Importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol. 2004;43:416-22.
14. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-7.
15. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure. Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-22.
16. Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42:728-35.
17. Svendstrup Nielsen L, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur Heart J. 2004;6:63-70.
18. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001;37:379-85.
19. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948-54.
20. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care. A randomized, controlled trial. J Am Coll Cardiol. 2003;42:1793-1800.
21. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea. N Engl J Med. 2004;350:647-54.
22. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-Type Natriuretic Peptide Testing in Patients with Acute Dyspnea. Arch Intern Med. 2006;166:1081-7.
23. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of b-type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart. 2005;91:606-12.
24. Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005;7:537-41.
25. Ray P, Arthaud M, Birolleau S, et al. Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. J Am Geriatr Soc. 2005;53:643-8.
26. Januzzi JL, van Rimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330-7.
27. Sykes E, Karcher RE, Eisenstadt J, et al. Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NT-proBNP. Am J Clin Pathol. 2005;123:584-90.
28. Wu AHB, Packer M, Smith A, et al. Analytic and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem. 2004;50:867-73.
29. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An Analysis from the breathing not properly multinational study. Am J Kidney Dis. 2003;41:571-5.
30. Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from Breathing Not Properly (BNP) Multinational Study. Am Heart J. 2004;147:1078-84.
31. Mueller C, Laule-Kilian K, Scholer A, et al. Use of B-Type Natriuretic Peptide for the Management of Women with Dyspnea. Am J Cardiol. 2004;94:1510-4.
32. Mueller C, Laule Kilian K, Scholer A, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int. 2005;67:278-84.
33. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594-600.
34. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med. 2004;164:2247-52.
35. Krauser DG, Llyod-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A proBNP Investigation of dyspnea in the emergency department (PRIDE) substudy. Am Heart J. 2005;149:744-50.
36. McLean AS, Tang B, Nalos M, Huang SJ, Stewart DE. Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients. Anaesth Intensive Care. 2003;31:21-7.
37. McLean AS, Huang SJ, Nalos M, Tang B, Stewart DE. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med. 2003;31:2611-8.
38. Charpentier J, luyt CE, Fulla Y, et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med. 2004;32:660-5.
39. Phua J, Lim TK, Lee KH. B-type natriuretic peptide: issues for the intensivist and pulmonologist. Crit Care Med. 2005;33:2094-103.
40. Brueckmann M, Huhle G, Lang S, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation. 2005;112:527-34.
41. Silver MA, Maisel A, Yancy CW, et al. BNP consensus panel 2004: a clinical approach for teh diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10(Suppl3):10-11.
42. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-41.
43. Verdiani V, Nozzoli C, Bacci F, et al. Pre-discharge B-type natriuretic peptide predidicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail. 2005;7:566-71.
44. Bettencourt P, Azevedo A, Pimenta J, et al. N-Terminal- Pro-Brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-74.
45. Tsutamoto T, Wada A, Maeda K. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-16.
46. Australia-New Zealand Heart Failure Group Richards AM, Doughty R, Nichols MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation. 1999;99:786-92.
47. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimised treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587-93.
48. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol. 2001;37:1781-7.
49. Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934-41.
50. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-30.
51. Jourdain P, Funck F, Gueffet P, et al. Benefit of BNP plasma levels for optimising therapy: the systolic heart failure treatment supported by BNP multicenter trial (STARS-BNP). J Am Coll Cardiol. 2005;45:1001-151 (abstract).
52. Wu AH, Smith A, Wieczorek S. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628-31.
53. Clerico A, Carlo Zucchelli G, Pilo A, Passino C, Emdin M. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med. 2006;44:366-78.
54. Lainchbury JG, Troughton RW, Frampton CM, et al. NT-proBNP guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail. 2006;8:532-8.
55. Brunner-La Rocca HP, Buser PT, Schindler R, et al. Management of elderly patients with congestive heart failure - design of the trial of intensified versus standard medical therapy in elderly patienst with congestive heart failure (TIME-CHF). Am Heart J. 2006;151:949-55.
56. Maisel A. The coming of age of natriuretic peptides. The emperor does have new clothes! J Am Coll Cardiol. 2006;47:61-4.
57. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci. 1995;88:551-6.
58. Nicholson S, Richards M, Espiner E, et al. Atrial and brain natriuretic peptide response to exercise in patients with ischemic heart disease. Clin Exp Pharmacol Physiol. 1993;20:535-40.
59. Sabatine MS, Morrow DA, deLemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004;44:1988-95.
60. Staub D, Jonas N, Zellweger M, et al. Use of N-terminal proB-type natriuretic peptide to detect myocardial ischemia. Am J Med. 2005;118:1287.e9-1287.e16.